Natco Pharma Regulatory Approval

Natco Pharma Capital Structure Change

Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.

Value

₹1,279 Cr

Natco Pharma Product Launch

Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.

Natco Pharma Other Announcement

Natco Pharma Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance submission.

Natco Pharma Share Pledge

Promoter V.C. Nannapaneni pledged 850,000 shares of Natco Pharma, valued at ₹67.10 Crore. This pledge creation increases encumbrance on promoter shareholding.

Value

₹67.10 Cr

Natco Pharma Fund Raise of ₹2,000 Cr

Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.

Value

₹2,000 Cr

Natco Pharma Annual General Meeting

Natco Pharma held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved all agenda items, including a fund-raising authorisation limit of Rs. 2,000 Crore.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.